Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

0.20

Mkt cap

1.9M

Volume

673K

High

0.20

P/E Ratio

-0.05

52-wk high

7.39

Low

0.19

Div yield

N/A

52-wk low

0.16

Alphabet Inc. reported first-quarter revenue of $80.539 billion, a 15% increase year-over-year, surpassing estimates. Earnings were $1.89 per share, beating forecasts. Alphabet announced a $70 billion share repurchase program and its first-ever quarterly dividend, causing shares to rise 11.9% in pre-market trading. Other stocks also moved significantly in pre-market trading, with notable gainers including Tevogen Bio Holdings, Pineapple Energy, and Freight Technologies, and losers such as Aclarion, Vincerx Pharma, and SCWorx Corp.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 12:18 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings (TVGN) led the gainers with a 75.3% increase, while Processa Pharma (PCSA) experienced the largest drop among the losers, falling 15.6%. Other notable movers included Cryo-Cell International (CCEL) and Moleculin Biotech (MBRX) with substantial gains, and SCWorx (WORX) and Nuwellis (NUWE) with notable losses.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 12:06 pm

In Thursday's after-market session, health care stocks saw significant movements. Tevogen Bio Holdings led the gainers with a 51.8% increase, while Vincerx Pharma experienced the largest drop among the losers, declining by 17.5%. ResMed and DexCom reported their Q3 and Q1 earnings, respectively, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 8:32 pm

Caterpillar Inc. shares fell by 6.6% after missing revenue estimates for Q1 fiscal 2024, despite beating EPS expectations. Other stocks experienced significant movements, with notable gainers including Barfresh Food Group and Safe & Green Holdings, and losers like E-Home Household Service Holdings and Chicken Soup for the Soul Entertainment.

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 5:57 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Aclarion, Processa Pharma, Akso Health Group, Eyenovia, Predictive Oncology, and IMAC Holdings were among the gainers, with Aclarion leading by a 66.7% increase. On the downside, Cyclacel Pharmaceuticals, Organogenesis Holdings, Xylo Technologies, Protagenic Therapeutics, American Oncology Network, and INVO Bioscience saw notable declines, with Cyclacel Pharmaceuticals dropping by 33.1%.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 4:31 pm

Aclarion, Inc. (ACON) shares surged following the announcement that its Nociscan solution will be utilized in the LIFEHAB trial for diagnosing and treating chronic low back pain. This development marks a significant milestone for Aclarion, potentially enhancing its market position and product validation.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:10 pm

Aclarion, Inc. (NASDAQ: ACON, ACONW) announced its Nociscan solution will be used in the LIFEHAB trial in Norway to evaluate diagnosis and treatment of chronic low back pain. The trial compares lumbar interbody fusion surgery with multidisciplinary rehabilitation and aims to begin enrollment in Q2 2024. Nociscan, a SaaS platform, helps physicians identify the source of low back pain by quantifying chemical biomarkers. This marks an important step towards achieving successful reimbursement in Norway's single-payer health system.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:20 pm

Aclarion Inc received a notice from Nasdaq on April 8 regarding delisting or failure to satisfy continued listing rules, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 8:04 pm

Stryve Foods shares plummeted by 25% due to a significant fourth-quarter revenue miss. Other stocks experienced notable movements, with VivoPower International surging 315% after announcing a merger, and Acorda Therapeutics dropping 83.5% following a Chapter 11 bankruptcy filing. Various companies reported financial results, mergers, and other significant updates affecting their stock prices.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 5:23 pm

In Tuesday's pre-market session, health care stocks showed significant movement. MSP Recovery, Serina Therapeutics, and CareMax were among the top gainers, with MSP Recovery leading at a 61.9% increase. On the downside, Acorda Therapeutics experienced a sharp decline of 75.1%, followed by Gritstone Bio and Verve Therapeutics. Notably, several companies released their Q4 earnings reports, influencing stock movements.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.